Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705786 | 0.87 | CYP2C19 (0.45) | SMN1; SMN2CYP2C19GPR119ALDH1A1CYP2D6 | |
| SCHEMBL7772470 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2C19GPR119ALDH1A1CYP2D6 | |
| SCHEMBL6363547 | 0.84 | CYP2C19 (0.44) | SMN1; SMN2CYP2C19GPR119ALDH1A1CYP2D6 | |
| SCHEMBL7774527 | 0.79 | MEN1 (0.43) | SMN1; SMN2CYP2C19ALDH1A1ACKR3 | |
| SCHEMBL7107121 | 0.78 | MMP13 (0.35) | — | |
| SCHEMBL5116966 | 0.78 | CYP2C19 (0.47) | SMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL7772734 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2C19ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL7110085 | 0.77 | USP21 (0.39) | ALDH1A1MAPT | |
| SCHEMBL7768806 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP2C19ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL5117748 | 0.77 | CYP2C19 (0.45) | SMN1; SMN2CYP2C19ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | SMN1; SMN2 172/4885CYP2C19 3106/4885GPR119 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.